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doi:10.1016/j.ejvs.2008.12.015Abstract Objective: To evaluate the early and intermediate outcome of a consecutive series
of emergency endovascular aneurysm repairs (eEVAR) of computed tomography (CT)-verified
infrarenal ruptured abdominal aortic aneurysm (rAAA) at a single tertiary referral centre.
Methods: Prospectively collected data of patients operated between April 2000 and October
2007 were retrospectively reviewed and all their pre-, intra- and postoperative imaging were
re-evaluated. Patient and procedural data were analysed using a Cox multiregression model.
Results: Ninety patients (86% men, aged 76 (7) years), were identified and included in the
analysis. Symptom duration was <3 h in 22% of patients, 3e24 h in 39% and >24 h in 39%. Mean
aneurysmal diameter was 73 (14) mm. All patients were treated with the COOK Zenith
stent-graft (56% bi-iliac and 44% uni-iliac). Sixty-one percent were haemodynamically unstable
on presentation, and 26% required an intra-operative aortic occlusion balloon to maintain
haemodynamic stability.
The 30-day and 1-year mortality rates were 27% and 37%, respectively. One-year aneurysm-
related mortality was 33%. Twenty-eight percent of patients required re-interventions during
the follow-up. The use of an aortic occlusion balloon and the presence of cerebrovascular
disease or obstructive lung disorder correlated significantly with 30-day mortality in the
multivariate analysis.
Conclusion: EVAR is a valid treatment option for rAAA when used as a first-line method for all
patients.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.33 10 00; fax: þ46 40 33 80 96.
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Figure 1 The use of intra-operative occlusion balloon29
(Latex, large diameter occlusion balloon or Coda balloon
catheter, www.cookmedical.com), as illustrated above, due to
severe preoperative haemodynamic instability was the only
procedure-related variable that correlated significantly with
the 30-day mortality (pZ 0.003, rr: 4.8, 95% CI: 1.7e13.0).
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Despite advances in operative technique and perioperative
care over the past 50 years, the results of emergency open-
surgical repair (eOR) of ruptured abdominal aortic aneu-
rysms (rAAA) remain dismal, with mortality rates in the 50%
range.1
Endovascular AAA repair (EVAR) was described in the
early 1990s by Parodi et al. and Volodos et al. and brought
aortic aneurysm repair into the age of minimally invasive
surgery.2,3 The use of EVAR for ruptured and symptomatic
aneurysms (elective EVAR, eEVAR) was described a few
years later,4,5 and it is presently being promoted as the
treatment of choice in the emergency setting.6 A number of
small series report mortality rates from 0% to 45% for
eEVAR,5,7e16 but a large variability, both in device selection
and in different pathologies treated, makes results hard to
interpret. Non-randomised studies comparing eEVAR to
elective open repair (eOR) indicate a lower 30-day
mortality for the former (0e34% vs. 0e54%),7e27 but the
number of eEVAR patients is small. The only prospective,
randomised, controlled trial published had a 30-day
mortality of 53% for both treatment modalities.28
The present study aims to report the early and inter-
mediate results of 90 consecutive eEVAR procedures from
a single referral centre.
Material and Methods
All patients with a computed tomography (CT)-confirmed
rAAA treated with eEVAR between April 2000 and October
2007 were included in this study. Pseudoaneurysms, symp-
tomatic aneurysms without evidence of rupture as well as
fenestrated and custom-made devices were excluded.
At our institution, all EVAR procedures are performed in
a hybrid operating room. Dedicated endovascular ancillary
staff is available at all times. Since eEVAR has been the
treatment of choice for rAAA at our department since 2001,
a vast majority of patients with rAAA are evaluated with CT
upon clinical suspicion of aneurysm rupture.
Data were prospectively registered in a local database.
For the purpose of the present study, all charts, CT scans
and angiograms were re-evaluated and verified and addi-
tional end-points collected. Data were then retrospectively
analysed. Mortality data were cross-referenced with the
Swedish National Population Registry.
Haemodynamic instability was defined as loss of
consciousness or systolic blood pressure< 80 mmHg before
induction of anaesthesia. Permissive hypotension was used
until exclusion of the aneurysm was achieved. Blood pres-
sure was regarded as satisfactory as long as the patient
remained conscious.29 Symptom duration was defined as
the time passed since presentation of first clinical sign of
rupture (i.e., pain, loss of consciousness, etc.).
Only the commercially available bi- or uni-iliac Zenith
stent-grafts (Cook Inc., USA) were used. The indication for
choosing a uni-iliac device was technical (e.g., unilateral
iliac occlusion or extreme tortuosity), clinical (extreme
urgency) or logistical (appropriate bi-iliac system not
available). Patients treated with an aorto-uni-iliac device
also received a femoro-femoral bypass.Standard iodised contrast (Omnipaque 140e
200 mgml1, GE Healthcare, www.gehealthcare.com) was
used in most cases. In patients with renal insufficiency,
standard contrast was replaced partially or fully by carbon
dioxide (CO2) at the surgeon’s discretion. No fixed creatinine
level was used for determining the choice of contrast. A
percutaneous approach was preferred using either a ‘pre-
close’ technique applying catheter-delivered sutures (Per-
close/Proglide, www.abbott.com) or a fascial closure
technique.30
If circulatory collapse occurred, an aortic occlusion
balloon (Latex, large diameter occlusion balloon or Coda
balloon catheter, www.cookmedical.com; Fig. 1) was
inserted transfemorally and inflated in the supra-visceral
aorta, as previously described in detail.29
The follow-up consisted of clinical examinations,
contrast-enhanced CT scans and plain abdominal radio-
graphs at 1 and 12 months, and then annually for the
remaining lifetime of the patient.
Morphological data were captured from thin-slice CT
scans (mostly 0.75e3 mm) performed with and without
intravenous contrast. Care was taken to locate the most
orthogonal projection to measure the shortest axial vessel
diameter to avoid overestimation of vessel size due to
tortuosity.
The local ethics committee at Lund University approved
the study.
All continuous variables were normally distributed,
except for the data regarding intensive care unit (ICU) and
Table 1 The coronary co-morbidity was defined as angina
pectoris, history of myocardial infarction, medication to
prevent or treat these conditions or previous re-vascular-
isation. Diabetes includes both insulin- or non-insulin-
dependent disease. Haemodynamic instability was defined
as loss of consciousness or recorded blood pressur-
e< 80 mmHg at any time preoperatively. The value of the
preoperative haemoglobin concentration did not take into
account the duration of symptoms or any intravenous fluid
given before the intervention. Cerebrovascular disease and
COPD correlated significantly to the 30-day mortality
(pZ 0.007, rr: 3.8, 95% CI: 1.4e10.5 and pZ 0.003, rr: 4.3,
95% CI: 1.7e11.0). The use of statins and body mass index
was not recorded in the database
Patient data
Number of patients 90 (14% female)
Age (years) 76 7
Co-morbidities
Coronary 37%
Heart failure 40%
Hypertension 64%
Cerebro vascular 20%
Renal insufficiencya 28%
Diabetes 14%
COPD 31%
Risk factors
Smoking 80%
Previous abdominal surgery 29%
Duration of symptoms (h)
<3 22%
3e24 39%
>24 39%
Haemodynamically unstable 61%
Preop haemoglobin (g l1) 102 19
Creatinine (mmol l1) 131 60
COPD, chronic obstructive pulmonary disease.
a Renal insufficiency: creatinine> 150 mmol l1, nZ 24 of 90)
or manifest (haemo- or peritoneal dialysis, nZ 3 of 90).
Table 2 All CT angiograms were re-evaluated and control
measurements were performed. The AAA morphology did
not influence the outcome and there was no significant
gender difference
AAA morphology (mm)
Aorta diameter 73 14
Proximal neck diameter 24 4
Neck length 21 10
>15 mm nZ 58
15 mm or less nZ 32
Right iliac diameter 18 6
Left iliac diameter 17 6
Ruptured AAA and Emergency EVAR 415hospital stay. Continuous data are presented as mean -
 standard deviation. Comparisons were performed with
standard Student’s t-test and the corresponding paired t-
test when appropriate. Non-normally distributed data are
presented as median and interquartile range. Binary data
were compared using the Fischer’s exact test. Cox multi-
variate regression analyses and KaplaneMeier for survival
curves were performed. All tests were two sided; p-val-
ues< 0.05 were considered significant. The SPSS software,
version 13.0, was used (www.spss.com).
Results
Ninety eEVAR procedures were identified and included in
the analysis. Patient data, AAA morphology, procedural
data, outcome and re-intervention rates are summarised in
Tables 1e4. Thirty-two patients (36%) had proximal aneu-
rysm necks 15mm or shorter in length. No graft-related
endoleaks (type 1 or 3) were left untreated.
None of the 90 eEVAR procedures was converted to open
repair. The all-cause 30-day mortality was 27% (24/90). Six
patients died perioperatively and another six within 24 h.
The remaining 12 patients died within 30 days due to
multiple organ failure (MOF) or myocardial infarction (MI).
Table 1 shows the co-morbidities and risk factors of the
patients. The patients had a mean of 4(2) co-morbidities
and risk factors (Table 1). No single patient was without any
co-morbidities or risk factors. In a multivariate regression
analysis testing the variables presented in Table 1, cere-
brovascular disease (pZ 0.007, relative risk, rr: 3.8, 95%
confidence interval (CI): 1.4e10.5) as well COPD
(pZ 0.003, rr: 4.3, 95% CI: 1.7e11.0) significantly corre-
lated to 30-day mortality. Among morphological and
procedure-related variables (specified in Tables 2 and 3),
only the use of the aortic occlusion balloon correlated
significantly to the 30-day outcome (pZ 0.003, rr: 4.8, 95%
CI: 1.7e13.0; Fig. 1).
Re-interventions
Twenty-four (27%) patients underwent re-interventions
during follow-up (Table 4). Eight open re-interventions
were performed, all in the immediate postoperative phase.
Seven of these underwent exploratory laparotomy for
bowel ischaemia (nZ 3), abdominal compartment
syndrome (nZ 3) or bleeding (nZ 1). Of these, only one
survived more than 30 days. One patient underwent
common femoral patch repair due to occlusion. Seven
patients underwent endovascular re-intervention: six
during late follow-up (two additional stenting of endograft
limbs due to kink, two embolisations due to type-2 endo-
leaks and expanding aneurysms, two proximal Palmaz stent
placement due to type-1 endoleak) and one early (diag-
nostic CO2 angiography only) due to worsened renal func-
tion postoperatively. Nine patients underwent combined
open and endovascular re-interventions postoperatively:
six in the acute phase (two diagnostic angiography and
exploratory laparotomy due to haemodynamic instability,
both negative; two superior mesenteric artery (SMA)
stenting and bowel resection due to iatrogenic SMA
coverage by the aortic stent-graft e both died in hospital;one iliac stent-graft and femoral interposition graft due to
external iliac artery rupture; one iliac stenting, open
balloon embolectomy and fasciotomy due to stent-graft
limb occlusion) and three in the late phase (one fenestrated
Table 3 The anaesthesia team estimated the procedural
time and the blood loss. These parameters included the
time and the amount of bleeding when the uni-iliac system
(44% of the cases) insertion was followed by the femoro-
femoral bypass. The transfusions are those given during the
first 24 h
Procedural data
Bi-iliac system 56%
Uni-iliac system 44%
Proximal stent-graft diameter 31 3
Anaesthesia form
General 50%
Local 50%
Occlusion balloon 26%
Procedural time (min) 207 82
Blood loss (ml) 1170 1230
Transfusion (U)
Packed red cells 6 5.4
Fresh frozen plasma 4 4
Table 4 Data on the time of hospitalisation have
a skewed distribution, hence presented as median and
interquartile range (all other data as mean and standard
deviation). The observed creatinine values are from the
patients who survived 30 days, patients that were on
permanent dialysis preoperatively excluded. The paired
comparison revealed a non-significant (pZ 0.343) increase.
The paired comparison between the original CT and latest
control revealed a significant (p< 0.001) shrinkage of the
AAA
Outcome
Conversions 0%
Length of care (days)
ICU 2 3
LOS 8 11
Follow-up (m)
Clinical 27 18
CT angiogram 24 15
30-Day mortality 27% (24/90)
1-year mortality
All-cause 37% (33/90)
Aneurysm-related 33% (30/90)
3-Year mortality 50%
Cause of death
30 Days Uniformly heart/vascular
related or multiple organ
failure
1 Year (non-aneurysm-
related)
2 neoplastic,
1 gastroenteritis
Creatinine (mmol l1)
Preoperatively 118 59
Last FU 133 118
Re-rupture 0%
Diameter change
over time (mm)
Preoperatively 73 14
Last FU 56 15
Detection of endoleak 4 Late type-1 endoleaks
treated
Migration during FU 0%
Re-intervention
Collectively 27% (24/90)
Open 8/25
Endovascular 7/25
Combination 9/25
416 J. Holst et al.proximal stent-graft extension due to proximal type-1
endoleak and femoral patch plasty; one open balloon
embolectomy and re-stenting of limb; one patient under-
went multiple re-interventions for type-1 endoleak and
limb occlusions, resulting finally in axillo-bifemoral bypass
and lower limb amputation 3 years after the rAAA).
The mean clinical follow-up was 27 months (18) and
the mean CT follow-up was 24 months (15). No patient
was lost to follow-up.
The cumulative survival data are presented in Fig. 2. The
1-year all-cause mortality was 37% (33 patients). Nine
patients died between the 2nd and 12th month. Six of the
deaths were related to the procedure and included MOF
(two), sepsis (one), MI (one), heart failure (one) and renal
failure (one). Three deaths were unrelated to the rAAA
(two malignancies and one gastroenteritis). Hence, the
1-year aneurysm-related death rate was 33% (30 of 90
cases). The 3-year survival rate was 50%.
Discussion
The majority of patients with rAAA die before reaching the
hospital, and it is estimated that only 10% reach the oper-
ating room alive.31 Despite advances in open-surgical repair
and preoperative care, the mortality for open repair of
rAAA remains between 45% and 50%.1 The massive surgical
trauma to the already massively traumatised patient with
an rAAA is a lethal combination. The theoretical advantages
to an endovascular approach are manifold. eEVAR can be
performed percutaneously under local anaesthesia, thus
avoiding the vasodilating and negatively inotropic effects of
general anaesthesia. Transfemoral access avoids the
devastating effects of a large, midline laparotomy on
muscle wall tone, which can lead to further circulatory
compromise. In addition, surgical dissection in the setting
of a large retroperitoneal haematoma is avoided and blood
loss is minimised. Lastly, EVAR also allows for continuousaortic flow, avoiding the effects of aortic cross-clamping
with potential reperfusion injury. The potential downsides
of eEVAR include technical, anatomical and logistical
issues. A preoperative CT is preferred, if not mandatory,
and can cause unnecessary delay in treatment. Several
studies, however, indicate that this plays a much lesser role
for the outcome of these patients than previously believed.
EVAR is also presently limited to patients with suitable
aneurysm necks and adequate access, and this will
Figure 2 The cumulative survival (KaplaneMeier) for all-
cause mortality after 30 days and 1 year was 73% and 63%,
respectively. The causes of death within the first month were
either multiple organ failure or myocardial/vascular. Two out
of three deaths that occurred between the 2nd and the 12th
month were aneurysm related. After 3 years, only half the
number of patients were alive.
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if strict criteria are used for inclusion. Logistically, the need
for appropriate intra-operative imaging, fully trained staff
as well as the availability of correct endograft inventory
also limits the widespread use of the technique.
Our data, with a 30-day mortality of 27%, correspond
well to the previously published smaller series with respect
to patient-, aneurysm-, procedure- and outcome/compli-
cation-related data. Furthermore, they correspond to the
recent meta-analyses by Lovegrove et al. of 463 patients
treated with eEVAR for rAAA.32 This is somewhat surprising
considering the very high rate of haemodynamically
unstable patients (61%) reflected in the high use of aortic
occlusion balloon (26%), in which the outcome proved to be
the worst. These acceptable results in the face of a high
proportion of unstable patients might be due to selection
bias and the fact that the report is not an intention-to-treat
analysis and can only be validated with further studies.
The limitations of the present series are inherent to
single-centre retrospective reports and, therefore, any
attempt at generalisation must be undertaken with
caution. In addition, no comparison to eOR under the same
study period was made. During the study period, there has
been a gradual shift towards eEVAR as presented earlier,24
and currently the amount of eEVAR by far exceeds eOR.
Therefore, any comparison may be unjust. Furthermore,
the precise number of rAAA patients, where no attempt at
repair, open or endovascular, was made is not known. It
might be argued that since we perceive eEVAR to be less
traumatic for patients with rAAA, we apply it more liberally
than we would with open repair. This will potentially affect
results negatively if older, sicker patients are treated and
thus produce worse outcome for EVAR than if stricter
inclusion criteria were applied. Conversely, themorphological and logistical issues might, in some cases,
disqualify patients for EVAR, forcing the unsuitable patients
to undergo open repair, perhaps thereby negatively
affecting the outcome for this group. Obviously, these
issues can be resolved only if randomised studies are
undertaken. There are, however, ethical issues being raised
regarding a randomised trial. If the results of EVAR were
truly as good as have been indicated in some studies and
the results of OR are quite stable and with mortality rates
of 40e50%, would it be ethically responsible to randomise
patients? Ultimately, this decision remains with the indi-
vidual physician or perhaps the institution that has to
scrutinise his/her/its own experience and the setting in
which treatment is offered.
Questions regarding the general applicability of eEVAR
compared to eOR have been raised, indicating that if strict
criteria for eEVAR are applied, only a minority of patients
can be treated. Accepting wider inclusion criteria (shorter,
wider necks or access problems) might negatively affect
the durability of the procedure. One must keep in
perspective, however, that the aim of elective versus
emergency treatment is quite different. In the former,
a good short-term outcome is guaranteed for most, and
thus long-term durability becomes paramount. In the
latter, short-term outcome is more uncertain and thus tips
the scale towards making this much more vital for the
choice of repair. Consequently, the role of eEVAR and its
ability to reduce immediate mortality speaks in its favour.
Neither the question of applicability or durability (as indi-
cated by secondary interventions) was specifically
addressed in this series. However, others have looked into
the matter. The overall applicability of eEVAR was
approximately only 30% of rAAA cases in one study.33 We
estimate that our applicability is considerably higher,
mainly due to a more favourable logistical setting and
a more aggressive approach. The rate of re-intervention in
our study was numerically (28%) higher compared to other
reports, where this parameter was the main end-point of
the study.15 This may, at least, be partly due to the policy
of having eEVAR as the first line of treatment of rAAA at our
department, thus accepting anatomical and clinical
parameters that will likely affect durability negatively.
Regardless of which modality is used to treat these very
ill patients, it is unlikely that the long-term all-cause
mortality will differ substantially as indicated in the rand-
omised trials of elective EVAR34,35 as well as the results in
the present study with a 50% survival rate 3 years after the
procedure. In the shorter perspective, it may even be likely
that the early and intermediate results of eEVAR will be less
favourable as more and more difficult cases are being
attempted. The future will probably reveal a final, appro-
priate equilibrium between eOR and eEVAR.
We believe that the favourable outcome in this large
consecutive series of eEVAR may be attributed to several
reasons. Firstly, the endovascular specialists, the vascular
surgeons and theproperly trainedancillary staff haveworked
together for a long time as ‘one’ team, accumulating a vast
collective experience in the elective setting. Secondly, the
in-house logistics allow us to evaluate every patient for
a possible eEVAR with a CT at all times. Thirdly, we have
deliberately chosen to use only one type of modular stent-
graft system (Cook Zenith system), thus allowing the entire
418 J. Holst et al.team to becomeaccustomed to a single device. The system is
commercially available and we find it versatile in almost
cases, as demonstrated by the 100% technical success rate in
excluding the rAAA in the acute phase.
It seems logical that in light of these and other
cautiously promising results, the increasing number of
elective EVARs with the parallel technical development of
both the stent-graft design/delivery and imaging will
further increase the use of eEVAR over eOR. Further studies
will determine the ultimate role of eEVAR versus eOR.
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